Conatus Pharmaceuticals (NASDAQ:CNAT) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.15) earnings per share for the quarter, hitting the consensus estimate of ($0.15), Fidelity Earnings reports. Conatus Pharmaceuticals had a negative return on equity of 69.68% and a negative net margin of 48.46%.
CNAT stock opened at $5.12 on Friday. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 0.68. The firm has a market cap of $125.10 million, a price-to-earnings ratio of -8.39 and a beta of 1.84. Conatus Pharmaceuticals has a fifty-two week low of $3.22 and a fifty-two week high of $7.95.
Several research analysts have weighed in on the company. Oppenheimer set a $14.00 price objective on Conatus Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, October 1st. ValuEngine upgraded Conatus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, September 22nd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $11.80.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
Recommended Story: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.